

Marque Pharmaceutique Sud- Américaine de 20 Ans





Marque Pharmaceutique Sud-Américaine de 20 Ans

Cette société est présente sur le marché colombien depuis 19 ans, elle possède les enregistrements INVIMA approuvés.

Il y a un besoin sérieux d'étendre le marché au Guatemala et à 5 autres pays d'Amérique centrale avec un grand distributeur. Il y a 289 pharmacies affiliées dans toutes les principales villes de Colombie et dans de nombreuses villes secondaires. Le CRM est très bien organisé, avec 1397 membres entre médecins, pharmacies et le marché institutionnel. Il y a 289 pharmacies affiliées dans toutes les principales villes de Colombie et dans de nombreuses villes secondaires.

Marché Commercial

- 75% des ventes sont réalisées par des médecins
- 25% des ventes sont institutionnelles

L'entreprise achète l'API, les excipients, l'emballage et les produits, et tout est fabriqué en sous-traitance dans des usines spécialisées en Colombie qui sont approuvées par l'INVIMA.

Actuellement, il y a 32 produits enregistrés et approuvés par l'INVIMA et la Surintendance de l'Industrie et du Commerce. Deux nouveaux produits sont sur le point d'être approuvés par l'INVIMA.

Une approbation par l'INVIMA en Colombie prend en moyenne 2 ans et 30 000 USD d'investissement à réaliser.

Cette entreprise propose 5 produits nutritionnels, dont nous possédons la marque, mais pas le registre.

Produits

- o Antibiotiques
- o Analgésiques
- o Anti-inflammatoire
- o Antihistaminiques
- o Maladies cardiovasculaires
- o Nutritionnel
- o gastroentérologie
- o Médicaments hypolipémiants
- o Produits pédiatriques: Antibiotiques et nutrition.

TARGET PRICE

\$11,500,000

GROSS REVENUE

2000000

EBITDA

450000

BUSINESS TYPE

Fabrication, Fabrication,
Pharmaceutique,
Pharmaceutique

ESTABLISHED

2002-06-22

SUPPORT & TRAINING

6 mois

REASON FOR SELLING

Retraite

COUNTRY

Colombie

BUSINESS ID

L#20210109

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM